METHODS FOR PREDICTING TUMOR REPONSE TO TARGETED THERAPIES
First Claim
Patent Images
1. A method of treating a patient having a solid tumor with a therapy comprising a VEGF pathway specific drugcomprising:
- (a) measuring two or more VEGF pathway biomarkers in a sample taken from a patient having a solid tumor to calculate an assigned score for each biomarker;
(b) calculating an aggregate score from at least two assigned scores, wherein an aggregate score above a predetermined cut off value calculated from retrospective samples indicates that the patient will benefit from administration of a therapy comprising a pathway specific drug; and
,(c) administering the therapy to the patient if the aggregate score indicates that the patient will benefit from the administration of the therapy.
2 Assignments
0 Petitions
Accused Products
Abstract
A method for identifying cancer patients that are likely to be responders or non-responders to a signal transduction pathway inhibitor is described.
20 Citations
36 Claims
-
1. A method of treating a patient having a solid tumor with a therapy comprising a VEGF pathway specific drug
comprising: -
(a) measuring two or more VEGF pathway biomarkers in a sample taken from a patient having a solid tumor to calculate an assigned score for each biomarker; (b) calculating an aggregate score from at least two assigned scores, wherein an aggregate score above a predetermined cut off value calculated from retrospective samples indicates that the patient will benefit from administration of a therapy comprising a pathway specific drug; and
,(c) administering the therapy to the patient if the aggregate score indicates that the patient will benefit from the administration of the therapy. - View Dependent Claims (4, 5, 6, 7, 8, 9, 10, 11, 12)
-
-
2. A method of determining whether a patient is in need of therapy to treat a solid tumor with a therapy comprising a VEGF pathway specific drug, comprising:
-
(a) calculating a aggregate score from at least two assigned score derived from the measurement of at least two VEGF pathway biomarkers in a sample taken from a patient having a solid tumor, (b) determining from the aggregate score whether the patient will benefit from the administration of a therapy comprising a pathway specific drug, wherein a aggregate score above a predetermined cut off value calculated from retrospective samples indicates that the patient will benefit from the administration of the therapy; and
,(c) administering the therapy to the patient in need thereof.
-
-
3. A method of treating a patient having a solid tumor with a therapy comprising a VEGF pathway specific drug comprising:
(a) determining from an aggregate score calculated from at least two assigned scores derived from measurement of at least two VEGF pathway biomarker proteins in a sample taken from a patient having a solid tumor, that the patient will benefit from administration of a therapy if the aggregated score is above a predetermined cut off value calculated from retrospective samples.
-
13. A method of treating a patient having a solid tumor with a therapy comprising a mTOR pathway specific drug
comprising: -
(a) measuring two or more mTOR pathway biomarkers in a sample taken from a patient having a solid tumor to calculate an assigned score for each biomarker; (b) calculating an aggregate score from at least two assigned scores, wherein an aggregate score above a predetermined cut off value calculated from retrospective samples indicates that the patient will benefit from administration of a therapy comprising a pathway specific drug; and
,(c) administering the therapy to the patient if the aggregate score indicates that the patient will benefit from the administration of the therapy. - View Dependent Claims (16, 17, 18, 19, 20, 21, 22, 23, 24, 25)
-
-
14. A method of determining whether a patient is in need of therapy to treat a solid tumor with a therapy comprising an mTOR pathway specific drug, comprising:
-
(a) calculating a aggregate score from at least two assigned score derived from the measurement of at least two mTOR pathway biomarkers in a sample taken from a patient having a solid tumor, (b) determining from the aggregate score whether the patient will benefit from the administration of a therapy comprising a pathway specific drug, wherein a aggregate score above a predetermined cut off value calculated from retrospective samples indicates that the patient will benefit from the administration of the therapy; and
,(c) administering the therapy to the patient in need thereof.
-
-
15. A method of treating a patient having a solid tumor with a therapy comprising an mTOR pathway specific drug comprising:
(a) determining from an aggregate score calculated from at least two assigned scores derived from measurement of at least two mTOR pathway biomarker proteins in a sample taken from a patient having a solid tumor, that the patient will benefit from administration of a therapy if the aggregated score is above a predetermined cut off value calculated from retrospective samples.
-
26. A method of treating a patient having a solid tumor with a therapy comprising a pathway specific drug
comprising: -
(a) measuring two or more pathway biomarkers in a sample taken from a patient having a solid tumor to calculate an assigned score for each biomarker, (b) calculating an aggregate score from at least two assigned scores, wherein an aggregate score above a predetermined cut off value calculated from retrospective samples indicates that the patient will benefit from administration of a therapy comprising a pathway specific drug; and
,(c) administering the therapy to the patient if the aggregate score indicates that the patient will benefit from the administration of the therapy. - View Dependent Claims (29, 30, 31, 32, 33, 34)
-
-
27. A method of determining whether a patient is in need of therapy to treat a solid tumor with a therapy comprising a pathway specific drug, comprising:
-
(a) calculating a aggregate score from at least two assigned score derived from the measurement of at least two pathway biomarkers in a sample taken from a patient having a solid tumor; (b) determining from the aggregate score whether the patient will benefit from the administration of a therapy comprising a pathway specific drug, wherein a aggregate score above a predetermined cut off value calculated from retrospective samples indicates that the patient will benefit from the administration of the therapy; and
,(c) administering the therapy to the patient in need thereof.
-
-
28. A method of treating a patient having a solid tumor with a therapy comprising a pathway specific drug comprising:
(a) determining from an aggregate score calculated from at least two assigned scores derived from measurement of at least two pathway biomarker proteins in a sample taken from a patient having a solid tumor, that the patient will benefit from administration of a therapy if the aggregated score is above a predetermined cut off value calculated from retrospective samples.
-
35. A method of treating a patient having a renal cell carcinoma (RCC) solid tumor with a therapy comprising a pathway specific drug
comprising: -
(a) measuring two or more pathway biomarkers in a sample taken from a patient having a solid tumor to calculate an assigned score for each biomarker; (b) calculating an aggregate score from at least two assigned scores, wherein an aggregate score above a predetermined cut off value calculated from retrospective samples indicates that the patient will benefit from administration of a therapy comprising a pathway specific drug; and
,(c) administering the therapy to the patient if the aggregate score indicates that the patient will benefit from the administration of the therapy.
-
-
36. A method of treating a patient having a breast cancer solid tumor with a therapy comprising a pathway specific drug
comprising: -
(a) measuring two or more pathway biomarkers in a sample taken from a patient having a solid tumor to calculate an assigned score for each biomarker; (b) calculating an aggregate score from at least two assigned scores, wherein an aggregate score above a predetermined cut off value calculated from retrospective samples indicates that the patient will benefit from administration of a therapy comprising a pathway specific drug; and
,(c) administering the therapy to the patient if the aggregate score indicates that the patient will benefit from the administration of the therapy.
-
Specification